Monitoring physical activity with either step counts or time spent exercising shows similar benefits in reducing cardiovascular disease and all-cause mortality among women in their 60s. Both methods support health guidelines and personal preference.
Biopharma firm Zetagen raises $9.79m in Series B financing round
In preclinical research, Zetagen’s ZetaMAST showed potential to stop lesion growth. Credit: Zetagen. Clinical-stage biopharma firm Zetagen Therapeutics has raised $9.79m in a Series B